Plus   Neg

Stock Alert: BioXcel Therapeutics (BTAI)

BioXcel Therapeutics Inc. (BTAI), which had a banner year in 2019, gaining a whopping 338%, is up an impressive 50% so far this year.

BioXcel Therapeutics is a clinical-stage biopharmaceutical company focused on drug development that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology.

The most advanced drug candidate in the pipeline is BXCL501, which is under a phase III program dubbed SERENITY, consisting of two phase III studies for the acute treatment of agitation in patients with schizophrenia and bipolar disorder. Topline data from both the phase III trials, known as SERENITY I and SERENITY II, are expected in mid-2020.

BXCL501 is also under a phase Ib/II study for the acute treatment of agitation in patients with dementia. Topline results are expected in mid-2020.

A phase Ib/II trial of BXCL501 for the treatment of opioid withdrawal symptoms, dubbed RELEASE, is also expected to be initiated soon.

Next up in the pipeline is BXCL701, which in combination with Keytruda, is under a phase Ib/II trial in treatment-emergent Neuroendocrine Prostate Cancer (tNEPC). Data read-out from this trial is expected in the first half of 2020.

As of September 30, 2019, the Company had cash and cash equivalents of roughly $40.3 million.

BTAI has traded in a range of $3.76 to $22.50 in the last 1 year. As of this writing, the stock is up 18.97% at $22.49.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT